Tucatinib + trastuzumab/pertuzumab mejora la supervivencia libre de progresión sin nuevas señales de seguridad y puede ser una opción para la terapia de mantenimiento de primera línea en pacientes con cáncer de mama metastásico HER2+ #HER2+ #MBC #Tucatini…
So far, Altmetric has seen
5 Bluesky posts from 5 Bluesky users, with an upper bound of 171 followers.
0 followers
47 followers
RP @jco-asco.bsky.social: 🚨 HER2+ MBC Maintenance News! 🚨 The Phase 3 HER2CLIMB-05 trial (Dieras et al.) was simultaneously published at #SABCS25. This study assesses Tucatinib vs. Placebo with Trastuzumab/Pertuzumab as first-line maintenance. 👉 See …
66 followers
🚨 HER2+ MBC Maintenance News! 🚨 The Phase 3 HER2CLIMB-05 trial (Dieras et al.) was simultaneously published at #SABCS25. This study assesses Tucatinib vs. Placebo with Trastuzumab/Pertuzumab as first-line maintenance. 👉 See the results: ascopubs.org/…
25 followers
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic #BreastCancer. ascopubs.org/doi/10.1200/...